IN2014DN00123A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN00123A IN2014DN00123A IN123DEN2014A IN2014DN00123A IN 2014DN00123 A IN2014DN00123 A IN 2014DN00123A IN 123DEN2014 A IN123DEN2014 A IN 123DEN2014A IN 2014DN00123 A IN2014DN00123 A IN 2014DN00123A
- Authority
- IN
- India
- Prior art keywords
- compounds
- mek
- inflammation
- inhibitors
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
The present invention relates to compounds (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases like cancer and inflammation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN123DEN2014 IN2014DN00123A (en) | 2011-06-09 | 2012-06-06 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1634DE2011 | 2011-06-09 | ||
CN201210175145 | 2012-05-31 | ||
PCT/IB2012/052860 WO2012168884A1 (en) | 2011-06-09 | 2012-06-06 | Heterocyclic sulfonamide derivatives |
IN123DEN2014 IN2014DN00123A (en) | 2011-06-09 | 2012-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2014DN00123A true IN2014DN00123A (en) | 2015-05-22 |
Family
ID=46384435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN123DEN2014 IN2014DN00123A (en) | 2011-06-09 | 2012-06-06 |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP2718276A1 (en) |
JP (1) | JP2014517004A (en) |
KR (1) | KR20140034898A (en) |
AU (1) | AU2012265844A1 (en) |
BR (1) | BR112013031201A2 (en) |
CA (1) | CA2838029A1 (en) |
EA (1) | EA201391820A1 (en) |
IN (1) | IN2014DN00123A (en) |
MX (1) | MX2013014398A (en) |
WO (1) | WO2012168884A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013094546A1 (en) * | 2011-12-19 | 2015-04-27 | 住友化学株式会社 | Method for producing sulfonate |
EP2742940B1 (en) | 2012-12-13 | 2017-07-26 | IP Gesellschaft für Management mbH | Fumarate salt of (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane for adminstration once daily, twice daily or thrice daily |
CN104886052B (en) * | 2015-06-02 | 2016-08-31 | 吉林省八达农药有限公司 | A kind of application of cyclopropyl-sulfonylamide |
EP3630746A1 (en) * | 2017-05-25 | 2020-04-08 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
WO2019183385A1 (en) * | 2018-03-22 | 2019-09-26 | University Of Rochester | Mapk/erk inhibition for ovarian and other cancers |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (en) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Ring gap magnet system |
GB1524747A (en) | 1976-05-11 | 1978-09-13 | Ici Ltd | Polypeptide |
ATE28864T1 (en) | 1982-07-23 | 1987-08-15 | Ici Plc | AMIDE DERIVATIVES. |
GB8327256D0 (en) | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
US5010099A (en) | 1989-08-11 | 1991-04-23 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds, compositions containing same and method of preparation and use |
US5395855A (en) | 1990-05-07 | 1995-03-07 | Ciba-Geigy Corporation | Hydrazones |
NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
TW225528B (en) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
AU687727B2 (en) | 1992-10-28 | 1998-03-05 | Genentech Inc. | Vascular endothelial cell growth factor antagonists |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
JP3088018B2 (en) | 1995-03-30 | 2000-09-18 | ファイザー・インコーポレーテッド | Quinazoline derivatives |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
US5843901A (en) | 1995-06-07 | 1998-12-01 | Advanced Research & Technology Institute | LHRH antagonist peptides |
US5880141A (en) | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
CZ1598A3 (en) | 1995-07-06 | 1998-04-15 | Novartis Ag | Pyrrolopyrimidines and process for preparing thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
CN100503580C (en) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | Irreversible inhibitor of tyrosine kinase |
CA2258548C (en) | 1996-06-24 | 2005-07-26 | Pfizer Inc. | Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases |
WO1998008849A1 (en) | 1996-08-30 | 1998-03-05 | Novartis Aktiengesellschaft | Method for producing epothilones, and intermediate products obtained during the production process |
WO1998010121A1 (en) | 1996-09-06 | 1998-03-12 | Obducat Ab | Method for anisotropic etching of structures in conducting materials |
DE19638745C2 (en) | 1996-09-11 | 2001-05-10 | Schering Ag | Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR) |
CA2265630A1 (en) | 1996-09-13 | 1998-03-19 | Gerald Mcmahon | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
EP0941227B2 (en) | 1996-11-18 | 2009-10-14 | Gesellschaft für biotechnologische Forschung mbH (GBF) | Epothilone d, production process, and its use as cytostatic as well as phytosanitary agent |
US6441186B1 (en) | 1996-12-13 | 2002-08-27 | The Scripps Research Institute | Epothilone analogs |
CO4950519A1 (en) | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
CO4940418A1 (en) | 1997-07-18 | 2000-07-24 | Novartis Ag | MODIFICATION OF A CRYSTAL OF A DERIVATIVE OF N-PHENYL-2-PIRIMIDINAMINE, PROCESSES FOR ITS MANUFACTURE AND USE |
GB9721069D0 (en) | 1997-10-03 | 1997-12-03 | Pharmacia & Upjohn Spa | Polymeric derivatives of camptothecin |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
WO1999043653A1 (en) | 1998-02-25 | 1999-09-02 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues therof |
BR9912938B1 (en) | 1998-08-11 | 2011-06-28 | isoquinoline derivatives, composition comprising them, process for preparation and use thereof. | |
GB9824579D0 (en) | 1998-11-10 | 1999-01-06 | Novartis Ag | Organic compounds |
UA71587C2 (en) | 1998-11-10 | 2004-12-15 | Шерінг Акцієнгезелльшафт | Anthranilic acid amides and use thereof as medicaments |
KR20070087132A (en) | 1998-11-20 | 2007-08-27 | 코산 바이오사이언시즈, 인코포레이티드 | Recombinant methods and materials for producing epothilone and epothilone derivatives |
ATE300957T1 (en) | 1998-12-22 | 2005-08-15 | Genentech Inc | ANTAGONISTS OF VASCULAR-ENDOTHELIAL CELL GROWTH FACTORS AND THEIR APPLICATION |
EP1165085B1 (en) | 1999-03-30 | 2006-06-14 | Novartis AG | Phthalazine derivatives for treating inflammatory diseases |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
GB0119249D0 (en) | 2001-08-07 | 2001-10-03 | Novartis Ag | Organic compounds |
JP2006083137A (en) * | 2004-09-17 | 2006-03-30 | Sankyo Co Ltd | Immunosuppressive agent |
CN101663279A (en) * | 2007-01-19 | 2010-03-03 | 阿迪生物科学公司 | inhibitors of mek |
UA99731C2 (en) * | 2007-07-30 | 2012-09-25 | Ардеа Биосайенсис, Инк | Crystalline polymorphic forms of n-(2-arylamino) aryl sulfonamides as inhibitors of mek, a composition (variants) and use |
EP2276747A1 (en) * | 2008-03-11 | 2011-01-26 | Cellzome Limited | Sulfonamides as zap-70 inhibitors |
BRPI0910175A2 (en) * | 2008-07-01 | 2017-03-21 | Genentech Inc | compound of formula i and ii, pharmaceutical composition, method of inhibiting abnormal cell growth or treating a hyperproliferative disorder in a mammal and method of treating an inflammatory disease in a mammal |
CA2761108A1 (en) * | 2009-04-21 | 2010-10-28 | Novartis Ag | Heterocyclic compounds as mek inhibitors |
CN102134218A (en) * | 2009-06-15 | 2011-07-27 | 凯美隆(北京)药业技术有限公司 | 6-aryl amino pyridone sulfamide and 6-aryl amino pymetrozine sulfamide methyl ethyl ketone (MEK) inihibitor |
AU2010317167B2 (en) * | 2009-11-04 | 2012-11-29 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as MEK inhibitors |
WO2011070030A1 (en) * | 2009-12-08 | 2011-06-16 | Novartis Ag | Heterocyclic sulfonamide derivatives |
-
2012
- 2012-06-06 CA CA2838029A patent/CA2838029A1/en not_active Abandoned
- 2012-06-06 IN IN123DEN2014 patent/IN2014DN00123A/en unknown
- 2012-06-06 EA EA201391820A patent/EA201391820A1/en unknown
- 2012-06-06 KR KR1020147000283A patent/KR20140034898A/en not_active Application Discontinuation
- 2012-06-06 JP JP2014514204A patent/JP2014517004A/en active Pending
- 2012-06-06 AU AU2012265844A patent/AU2012265844A1/en not_active Abandoned
- 2012-06-06 EP EP12730043.2A patent/EP2718276A1/en not_active Withdrawn
- 2012-06-06 MX MX2013014398A patent/MX2013014398A/en unknown
- 2012-06-06 WO PCT/IB2012/052860 patent/WO2012168884A1/en active Application Filing
- 2012-06-06 BR BR112013031201A patent/BR112013031201A2/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
MX2013014398A (en) | 2014-03-21 |
CA2838029A1 (en) | 2012-12-13 |
BR112013031201A2 (en) | 2017-01-31 |
KR20140034898A (en) | 2014-03-20 |
JP2014517004A (en) | 2014-07-17 |
EA201391820A1 (en) | 2014-12-30 |
EP2718276A1 (en) | 2014-04-16 |
AU2012265844A1 (en) | 2013-05-02 |
WO2012168884A1 (en) | 2012-12-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
AU2012214029A8 (en) | Rorgammat inhibitors | |
IN2015DN01156A (en) | ||
IN2014KN00769A (en) | ||
MY185206A (en) | Therapeutically active compounds and their methods of use | |
CR20200479A (en) | Therapeutically active compounds and their methods of use | |
MX2011011083A (en) | Heterocyclic compounds as mek inhibitors. | |
TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
IN2014MN00948A (en) | ||
MX349159B (en) | Deuterated derivatives of ivacaftor. | |
EP2750694B8 (en) | Methods and compositions relating to p62 for the treatment and prophylaxis of cancer | |
IN2014MN00987A (en) | ||
IN2015DN01119A (en) | ||
PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
MX2014012477A (en) | Pyrrolopyrazone inhibitors of tankyrase. | |
MX348726B (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation. | |
MX353762B (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation. | |
WO2015003355A3 (en) | Therapeutically active compounds and their methods of use | |
MX2013012977A (en) | Thiazole derivatives. | |
MX2014003376A (en) | Benzoic acid derivatives as eif4e inhibitors. | |
EA032271B9 (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
IN2014DN00123A (en) | ||
TN2012000242A1 (en) | Heterocyclic sulfonamide derivatives | |
MX2015007945A (en) | Uses and methods for the treatment of liver diseases or conditions. | |
IN2014DN03010A (en) |